• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Obstetricians and Public Cord Blood Banking

July 20, 2012

A survey by the National Marrow Donor Program found that obstetricians are familiar with the use of donated cord blood in transplantation, according to results published in the journal Transfusion.  However, 49% of surveyed obstetricians suggested that they did not feel they had sufficient information to answer patient questions about the procedure.  Umbilical cord blood transplants (UCBT), an experimental treatment since 1989, is now an accepted therapy for allogeneic transplant.  Further education could open more doors in potential therapeutic uses of umbilical cord blood transplants.


Reference

Walker T, Steckler D, Spellman S, Haven D, Welte K, Boo M. Awareness and acceptance of public cord blood banking among practicing obstetricians in the United States. Transfusion 2012;52: 787-93.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Urgent Global Need of Blood Products

  • Behavior Modifications Support Changes to Restrictive RBC Transfusion Practices

  • Transfusions and Hospital IV Injections Likely Contributed to the Spread of HIV and Other Blood-borne Viruses in Africa

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Pre-Hospital Resuscitation with Low-Titer Type O Whole Blood for Trauma Patients

  • Double-knotting Blood Storage Bag Tubing Reduces Contamination

  • Costs of Type & Screen and Crossmatch Laboratory Tests for RBCs Higher in U.S. Compared to U.K.

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley